Group 1 - The Hang Seng Index rose by 0.03%, gaining 8 points to close at 26,158 points, while the Hang Seng Tech Index fell by 0.06%. The morning trading volume was HKD 135.2 billion [1] - Three new stocks had significant gains on their first trading day: MINIMAX-WP (00100) surged by 78%, Jin Xun Resources (03636) increased by 22%, and Rebio Biotech-B (06938) rose by 28% [1] Group 2 - The stock of Damo Intelligence (02513) continued to rise by over 14% on its second day of trading [2] - The commercial aerospace sector remains hot, with Guangzhou accelerating its commercial aerospace layout, benefiting industry chain companies. Asia Pacific Satellite (01045) rose by 15.62%, and Goldwind Technology (002202) (02208) increased by 5% [2] - Lithium battery stocks saw a general increase, with the Ministry of Industry and Information Technology warning against irrational competition in the lithium battery industry. Zhong Chuang Xin Hang (03931) rose over 4%, and Ganfeng Lithium (002460) (01772) increased by 2% [2] - Gold stocks mostly rose due to geopolitical risks and interest rate cut expectations, with several gold mining companies issuing positive earnings forecasts. Shandong Gold (600547) (01787) rose by 6%, and Zhaojin Mining (01818) increased by 4.8% [2] Group 3 - Fubo Group (03738) rose by over 9% as the National Bureau of Statistics strengthened data technology innovation, with the "14th Five-Year Plan" set to deepen the development and utilization of data resources [3] Group 4 - Jiaxin International Resources (03858) rose by over 5% after its subsidiary won a contract for the Bakuta tungsten mine stripping project, valued at approximately HKD 227 million [4] - Lens Technology (300433) (06613) surged over 10% after Strong Brain Technology confirmed the completion of approximately HKD 2 billion financing, with the company exclusively undertaking mass production of its core hardware modules [4] - Weichai Power (000338) (02338) rose by over 5% after a leading US SOFC company secured a USD 2.65 billion order, and the company previously obtained manufacturing licenses for Ceres SOFC [4] Group 5 - Risen International (00842) plummeted by 64% as its subsidiary went public in the US, marking the first day of trading based on the ex-rights benchmark [5]

Core Viewpoint - Suzhou Ribo BioTechnology Co., Ltd. (Ribo Bio) officially listed on the Hong Kong Stock Exchange on January 9, 2026, with a market capitalization exceeding HKD 12 billion, marking a significant milestone in China's small nucleic acid drug industry [3][5]. Company Overview - Founded in 2007, Ribo Bio is a global leader in the research and development of small interfering RNA (siRNA) drugs and one of the earliest pioneers in this field in China [3][4]. - The company has established a comprehensive small nucleic acid drug technology platform that supports all stages of drug development, from early research to commercialization [4]. Technology and Product Pipeline - Ribo Bio has developed the RiboGalSTARTM platform based on proprietary intellectual property and clinically validated GalNAc delivery technology, with a rich product pipeline in cardiovascular, metabolic, liver, kidney diseases, and other therapeutic areas, advancing multiple products into clinical phases II and III [4][6]. Investment Journey - Ribo Bio has received investments from numerous well-known institutions, with Panlin Capital being a significant early investor since 2015, providing crucial funding during challenging times for the company [4][6]. - Panlin Capital's investment strategy focuses on identifying innovative drug development companies addressing unmet clinical needs, aligning with Ribo Bio's mission [6][7]. Milestones and Achievements - The successful IPO of Ribo Bio represents a key achievement for Panlin Capital, following their previous success with another biotech company, highlighting their commitment to supporting the long-term development of China's innovative drug industry [5][8]. - Ribo Bio's journey from a scientific laboratory to the global capital market illustrates the potential of small nucleic acid technology as a new wave in modern pharmaceuticals, capable of targeting intracellular proteins and addressing significant clinical needs [6][7].